Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Eu-1111
- Development stage
- Preclinical
- Lead developer
- Altimmune
- Modality
- Peptides
- Administration
- Inhalation
01
Overview
Eu-1111 is a long-acting peptide agonist of the vasoactive intestinal polypeptide receptor 2 (VPAC2) under development by EuMederis Pharmaceuticals. Formulated for inhalation, Eu-1111 is designed to target pulmonary hypertension. By selectively activating VPAC2, the drug aims to promote vasodilation and reduce pulmonary vascular resistance, offering a potential therapeutic option for patients with pulmonary hypertension.
02
Targets
VIPR2 (Vasoactive intestinal polypeptide receptor 2)
Beyond the preview
Go deeper on Eu-1111.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Eu-1111.